2014
Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.
Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, De Wit R, De Bono J, Cruz F, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak D, Lee C, Tejura B, Borgstein N, Dreicer R. Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel. Journal Of Clinical Oncology 2014, 32: 5042-5042. DOI: 10.1200/jco.2014.32.15_suppl.5042.Peer-Reviewed Original Research
2012
P114 Safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results from a phase 1/2 study
Petrylak D, Gandhi J, Clark W, Heath E, Lin J, Oh W, Agus D, Carthon B, Moran S, Mortimer P, Liu G. P114 Safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results from a phase 1/2 study. European Urology Open Science 2012, 11: 230. DOI: 10.1016/s1569-9056(13)60480-7.Peer-Reviewed Original Research